Focus: China pharma projects disrupted by Sino-US tensions

Sino-US trade tensions are prompting Chinese pharmaceutical research and development firms, including WuXi AppTec and WuXi Biologics, to adjust project plans by stockpiling supplies, considering local testing of U.S. clinical samples, and seeking non-U.S. alternatives for reagents, potentially increasing costs and causing delays. Companies are worried about access to U.S. supply chains and potential import tariffs, leading some to avoid or delay projects, with reliance on U.S. imports, such as diagnostic and laboratory reagents valued at $1.4 billion in 2024, coming under scrutiny.

Analysis

Sino-US trade tensions are creating significant operational disruptions and strategic reassessments for Chinese pharmaceutical research and development firms, including prominent players like WuXi AppTec (603259.SS) and WuXi Biologics (2269.HK). These companies, integral to the global pharmaceutical supply chain serving giants such as Pfizer and AstraZeneca, are actively altering project plans, stockpiling essential supplies like U.S.-made reagents, and exploring options such as localizing the testing of U.S. clinical samples to mitigate risks associated with uncertain U.S. supply chain access and fluctuating import tariffs, which had risen to as much as 125% before being reduced to 10% pending a durable trade resolution. This reliance is underscored by 2024 U.N. Comtrade data showing U.S. exports of diagnostic and laboratory reagents to China valued at approximately $1.4 billion. Specific instances of disruption include WuXi AppTec and a client pausing a Hepatitis B pre-clinical research project to switch from U.S.-made reagents due to cost concerns, and at least 17 Chinese biotech clients requesting local manufacturer JS Biosciences to maintain backup raw materials since April. Furthermore, some firms are reconsidering project initiations or declining new business, as seen with a Chinese R&D firm forgoing a quotation for protein drug manufacturing due to delays in obtaining U.S.-made culture medium from a Fujifilm subsidiary, a process that typically takes two to four months. The shift towards testing U.S. samples in-country, as discussed by Innovent Biologics and BeOne Medicines with Thermo Fisher Scientific, is anticipated to increase operational costs. The prevailing sentiment is moderately negative and cautious, reflecting widespread industry concern over the unpredictable long-term policy environment and its impact on project timelines and R&D expenditure.

Key Decisions for Investors

• Investors should closely monitor Chinese pharmaceutical CROs and CDMOs, such as WuXi AppTec and WuXi Biologics, for margin compression and revenue impacts stemming from increased operational costs, project delays, and supply chain reconfigurations driven by U.S.-China trade friction.
• Evaluate the potential for a strategic shift towards domestic sourcing of critical R&D materials within China, which could present opportunities for local suppliers but pose risks for U.S. and international exporters like Thermo Fisher Scientific and Fujifilm facing reduced demand or increased competition.
• Given the heightened geopolitical uncertainty and its direct impact on the pharmaceutical sector, investors should prioritize companies demonstrating robust supply chain resilience, proactive risk mitigation strategies, and an ability to adapt to a potentially more fragmented global R&D landscape.